NCT04583800|Recruiting
Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes
PreciDIAB-H&B
Loading search results
PreciDIAB-H&B
Sponsor study identifier
Secondary identifiers
OTHER · ID-RCB number,ANSM
observational
600
1 country
1
Study Start
June 22, 2021
Actual (reported)Primary Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Type 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its early stage is often silent. At present, primary prevention for heart failure is not available. Our aim is to identify diabetic patients at risk of heart failure in order to develop personalized preventive strategies. Type 2 diabetes is vascular and metabolic risk factor for cognitive decline though a direct lesional effect but also through an interaction with underlying neurodegenerative lesions. Our aim is to identify diabetic patients at risk of cognitive decline in order to develop personalized preventive strategies
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 28, 2020
Actual (reported)October 12, 2020
Actual (reported)June 22, 2021
Actual (reported)June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Heart failure (≥ stade B).
at 48 months
Cognitive decline (composite endpoint)
at 48 months
Major cardio-neuro-vascular events
at 48 months
People with type 2 diabetes and free of heart failure (≥stade B).
Hopital Roger Salengro, CHU Lille
Lille, 59037, France
Blood sample
Charlotte Cordonnier, MD,PhD
University Hospital, Lille
First Submitted
September 28, 2020
First Posted
October 12, 2020
Study Start
June 22, 2021
Actual (reported)Primary Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure
Contact the study team to confirm eligibility.
Study Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 23, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: